Literature DB >> 23943423

Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.

Grigoriy A Yanus1, Anna V Belyaeva, Alexandr O Ivantsov, Ekatherina Sh Kuligina, Evgeny N Suspitsin, Natalia V Mitiushkina, Svetlana N Aleksakhina, Aglaya G Iyevleva, Olga A Zaitseva, Olga S Yatsuk, Tatiana V Gorodnova, Tatiana N Strelkova, Sofia A Efremova, Alla Yu Lepenchuk, Altn N Ochir-Garyaev, Moisey B Paneyah, Dmitriy E Matsko, Alexandr V Togo, Evgeny N Imyanitov.   

Abstract

One hundred and ninety-five consecutive surgically treated Russian colorectal cancer (CRC) patients were retrospectively analyzed for the presence of mutations in KRAS, NRAS, BRAF and PIK3CA genes as well as for the microsatellite instability status. Comparison between high-resolution melting analysis, co-amplification at lower denaturation temperature PCR, DNA sequencing and allele-specific PCR for the detection of KRAS codon 12/13 mutations revealed that none of these methods alone provided satisfactory results in 100 % of the analyzed cases; this experience supports the use of more than one mutation-detecting technique at least in some circumstances. KRAS codon 12/13 substitutions were detected in 70 (35.9 %) CRC cases. Other mutations in the RAS/RAF genes occurred in 22 (11.3 %) cases and included rare KRAS (n = 6), NRAS (n = 8) and BRAF (n = 8) alterations. 5 BRAF mutations affected codon 600, while the remaining 3 potentially functional substitutions were located in the position 594. Twenty-four (12.3 %) CRC cases carried mutations in the PIK3CA, and 18 of these tumors also contained activating alteration in the RAS/RAF genes (p = 0.007). Only 3 (1.5 %) CRC cases showed high-level microsatellite instability (MSI-H) as determined by a panel of mononucleotide markers. Overall, the distribution of potentially predictive mutations in Russian CRC cases is similar to the one observed in other patient series of European descent. Noticeable occurrence of D594G mutation in BRAF oncogene and low frequency of MSI-H may deserve specific attention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23943423     DOI: 10.1007/s12032-013-0686-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  31 in total

1.  Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue.

Authors:  Mi Jung Kwon; Seung Eun Lee; So Young Kang; Yoon-La Choi
Journal:  Pathol Res Pract       Date:  2011-11-08       Impact factor: 3.250

2.  PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.

Authors:  Shuangjie Wu; Yu Gan; Xinhai Wang; Jun Liu; Mengjun Li; Yifan Tang
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-24       Impact factor: 4.553

3.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Authors:  Wendy De Roock; Bart Claes; David Bernasconi; Jef De Schutter; Bart Biesmans; George Fountzilas; Konstantine T Kalogeras; Vassiliki Kotoula; Demetris Papamichael; Pierre Laurent-Puig; Frédérique Penault-Llorca; Philippe Rougier; Bruno Vincenzi; Daniele Santini; Giuseppe Tonini; Federico Cappuzzo; Milo Frattini; Francesca Molinari; Piercarlo Saletti; Sara De Dosso; Miriam Martini; Alberto Bardelli; Salvatore Siena; Andrea Sartore-Bianchi; Josep Tabernero; Teresa Macarulla; Frédéric Di Fiore; Alice Oden Gangloff; Fortunato Ciardiello; Per Pfeiffer; Camilla Qvortrup; Tine Plato Hansen; Eric Van Cutsem; Hubert Piessevaux; Diether Lambrechts; Mauro Delorenzi; Sabine Tejpar
Journal:  Lancet Oncol       Date:  2010-07-08       Impact factor: 41.316

4.  K-ras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes.

Authors:  Dmitry Kislitsin; Aaron Lerner; Gad Rennert; Zeev Lev
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

5.  Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

Authors:  Marc Peeters; Kelly S Oliner; Alex Parker; Salvatore Siena; Eric Van Cutsem; Jing Huang; Yves Humblet; Jean-Luc Van Laethem; Thierry André; Jeffrey Wiezorek; David Reese; Scott D Patterson
Journal:  Clin Cancer Res       Date:  2013-01-16       Impact factor: 12.531

Review 6.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

7.  Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.

Authors:  Grazia Palomba; Maria Colombino; Antonio Contu; Bruno Massidda; Giovanni Baldino; Antonio Pazzola; MariaTeresa Ionta; Francesca Capelli; Vittorio Trova; Tito Sedda; Giovanni Sanna; Francesco Tanda; Mario Budroni; Giuseppe Palmieri; Antonio Cossu; Marta Contu; Angelo Cuccu; Antonio Farris; Antonio Macciò; Giuseppe Mameli; Nina Olmeo; Salvatore Ortu; Elisabetta Petretto; Valeria Pusceddu; Luciano Virdis
Journal:  J Transl Med       Date:  2012-08-29       Impact factor: 5.531

8.  Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients.

Authors:  A S Soliman; M L Bondy; S A El-Badawy; N Mokhtar; S Eissa; S Bayoumy; I A Seifeldin; P S Houlihan; J R Lukish; T Watanabe; A O Chan; D Zhu; C I Amos; B Levin; S R Hamilton
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

9.  Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Authors: 
Journal:  Genet Med       Date:  2013-02-21       Impact factor: 8.822

10.  High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue.

Authors:  Jolien Tol; Jeroen R Dijkstra; Marianne E Vink-Börger; Iris D Nagtegaal; Cornelis J A Punt; Johan H J M Van Krieken; Marjolijn J L Ligtenberg
Journal:  J Cell Mol Med       Date:  2010-05-13       Impact factor: 5.310

View more
  19 in total

1.  KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.

Authors:  Ju-Xiang Ye; Yan Liu; Yun Qin; Hao-Hao Zhong; Wei-Ning Yi; Xue-Ying Shi
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

Authors:  Humaid O Al-Shamsi; Jeremy Jones; Yazan Fahmawi; Ibrahim Dahbour; Aziz Tabash; Reham Abdel-Wahab; Ahmed O S Abousamra; Kenna R Shaw; Lianchun Xiao; Manal M Hassan; Benjamin R Kipp; Scott Kopetz; Amr S Soliman; Robert R McWilliams; Robert A Wolff
Journal:  J Gastrointest Oncol       Date:  2016-12

3.  Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.

Authors:  Evgeny N Suspitsin; Grigory A Yanus; Anna P Sokolenko; Olga S Yatsuk; Olga A Zaitseva; Alexandr A Bessonov; Alexandr O Ivantsov; Valeria A Heinstein; Valery F Klimashevskiy; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2014-01-12       Impact factor: 3.064

4.  Highly Sensitive and Reliable Detection of EGFR Exon 19 Deletions by Droplet Digital Polymerase Chain Reaction.

Authors:  Natalya Oskina; Igor Oscorbin; Evgeniy Khrapov; Ulyana Boyarskikh; Dmitriy Subbotin; Irina Demidova; Evgeny Imyanitov; Maxim Filipenko
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

5.  A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population.

Authors:  Hafeez Afolabi; Salzihan Md Salleh; Zaidi Zakaria; Ch'ng Ewe Seng; Siti Norasikin Binti Mohd Nafil; Ahmad Aizat Bin Abdul Aziz; Yusuf Wada; Ahmad Irekeola
Journal:  Biomed Res Int       Date:  2022-06-23       Impact factor: 3.246

6.  Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations.

Authors:  Anna P Sokolenko; Nikita M Volkov; Elena V Preobrazhenskaya; Evgeny N Suspitsin; Aigul R Garifullina; Alexandr V Ivantsov; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Mol Biol Rep       Date:  2016-03-07       Impact factor: 2.316

7.  Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.

Authors:  Swati Bisht; Firoz Ahmad; Satyakam Sawaimoon; Simi Bhatia; Bibhu Ranjan Das
Journal:  Med Oncol       Date:  2014-07-30       Impact factor: 3.064

8.  First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.

Authors:  Vladimir M Moiseyenko; Fedor V Moiseyenko; Grigoriy A Yanus; Ekatherina Sh Kuligina; Anna P Sokolenko; Ilya V Bizin; Alexey A Kudriavtsev; Svetlana N Aleksakhina; Nikita M Volkov; Vyacheslav A Chubenko; Kseniya S Kozyreva; Mikhail M Kramchaninov; Alexandr S Zhuravlev; Kseniya V Shelekhova; Denis V Pashkov; Alexandr O Ivantsov; Aigul R Venina; Tatyana N Sokolova; Elena V Preobrazhenskaya; Natalia V Mitiushkina; Alexandr V Togo; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Clin Drug Investig       Date:  2018-06       Impact factor: 2.859

9.  Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer.

Authors:  Elisa Danese; Anna Maria Minicozzi; Marco Benati; Martina Montagnana; Elisa Paviati; Gian Luca Salvagno; Gabriel Lima-Oliveira; Milena Gusella; Felice Pasini; Giuseppe Lippi; Gian Cesare Guidi
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

10.  Clinical case of the neoadjuvant treatment with nivolumab in a patient with microsatellite unstable (MSI-H) locally advanced gastric cancer.

Authors:  Viacheslav Chubenko; Gamzat Inusilaev; Evgeny Imyanitov; Vladimir Moiseyenko
Journal:  BMJ Case Rep       Date:  2020-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.